ELAVL1 and cancer: The ability of HuR-FNP to reduce Bcl2, an anti-apoptotic protein that has been shown to play a key role in cell survival and contribute to resistance against cytotoxics [34, 50], provides new opportunity for testing HuR-FNP efficacy in Bcl-2 overexpressing drug-resistant cancer cells.